Projecting future drug expenditures - 2011

American Journal of Health-System Pharmacy

Volumn 68, Issue 10, 2011, Pages 921-932

  Doloresco, Fred ^a   Fominaya, Cory ^a   Schumock, Glen T ^b   Vermeulen, Lee C ^c,d   Matusiak, Linda ^e   Hunkler, Robert J ^e   Shah, Nilay D ^f,g   Hoffman, James M ^h,i  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c University of Wisconsin Health   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e IQVIA   (United States)

^f Mayo Clinic   (United States)

^g MAYO CLINIC   (United States)

^h ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

ⁱ UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Ambulatory care; Costs; Drugs; Economics; Health care; Hospitals; Prescriptions; Product development; United states

Indexed keywords

ALFUZOSIN; AMLODIPINE PLUS ATORVASTATIN; APIXABAN; ATORVASTATIN; BELIMUMAB; BOCEPREVIR; CAPECITABINE; CLADRIBINE; EXEMESTANE; FENOFIBRATE; GENERIC DRUG; IPILIMUMAB; LATANOPROST; LETROZOLE; LEVOFLOXACIN; OLANZAPINE; PROPAFENONE; RIVAROXABAN; TAZAROTENE; TELAPREVIR; TICAGRELOR; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; VORAPAXAR; ZAFIRLUKAST;

ACNE; ALLERGIC RHINITIS; ASTHMA; BREAST CANCER; COLON CANCER; DRUG COST; DRUG INDICATION; DYSLIPIDEMIA; FUTUROLOGY; GLAUCOMA; HEART ARRHYTHMIA; HEPATITIS C; HYPERTENSION; INFECTION; LUPUS ERYTHEMATOSUS; MELANOMA; MULTIPLE SCLEROSIS; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; REVIEW; SCHIZOPHRENIA;

EID: 79957658137     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100712     Document Type: Review

References (36)

1. IMS Health National Sales Perspectives. Analysis conducted by the authors. Analysis conducted July-December 2010.
2. Hoffman JM, Doloresco F, Vermeulen LC et al. Projecting future drug expenditures - 2010. Am J Health-Syst Pharm. 2010; 67:919-28.
3. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures - 2009. Am J Health-Syst Pharm. 2009; 66:237-57.
4. Cutler DM. The demise of the block-buster? N Engl J Med. 2007; 356:1292-3.
5. Food and Drug Administration. Drug and biologic approval reports. www. fda.gov/Drugs/Development ApprovalProcess/HowDrugsare DevelopedandApproved/ Drugand BiologicApprovalReports/default.htm (accessed 2010 Dec 27).
6. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures - 2004. Am J Health-Syst Pharm. 2004; 61:145-58. (Pubitemid 39004639)
7. Lee TH. "Me-too" products - friend or foe? N Engl J Med. 2004; 350:211-2.
8. Rogers EM. Diffusion of innovations. 4th ed. New York: Free Press; 1995.
9. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures - 2006. Am J Health-Syst Pharm. 2006; 63:123-38. (Pubitemid 43100358)
10. Hylek EM. Therapeutic potential of oral factor Xa inhibitors. N Engl J Med. 2010; 363:2559-61.
11. Schirmer SH, Baumhakel M, Neuberger HR et al. Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments. J Am Coll Cardiol. 2010; 56:2067-76.
12. Medco. 2010 drug trend report. Vol. 12. www.drugtrend.com/art/drug-trend/ pdf/DT-Report-2010.pdf (accessed 2010 Nov 20).
13. Eli Lilly & Co. et al. v. Zenith Goldline Pharma et al., Nos. 05-1396, -1429, and -1430 (Fed. Cir. 2006).
14. Food and Drug Administration. Paragraph IV patent certifications. www. fda.gov/Drugs/Development ApprovalProcess/HowDrugsare DevelopedandApproved/ Approval Applications/AbbreviatedNewDrug Appl i cat i onANDAGener ics /ucm 047676.htm (accessed 2010 Nov 20).
15. U.S. Patent Trade Office. Patent trade extensions. www.uspto.gov/patents/ resources/terms/156.jsp (accessed 2010 Nov 13).
16. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures - 2008. Am J Health-Syst Pharm. 2008; 65:234-53. (Pubitemid 351220774)
17. Thompson CA. FDA approves first generic enoxaparin product. Am J Health-Syst Pharm. 2010; 67:1486,1488. News.
18. Voelker R. FDA approves generic enoxaparin. JAMA. 2010; 304:844. News.
19. Food and Drug Administration. FDA approves first generic enoxaparin sodium injection. www.fda.gov/News Events/Newsroom/PressAnnouncements/ ucm220092.htm (accessed 2010 Dec 20).
20. Food and Drug Administration. Establishing active ingredient sameness for a generic enoxaparin sodium, a low molecular weight heparin. www.fda.gov/ Drugs/DrugSafety/PostmarketDrug SafetyInformationforPatientsand Providers/ucm220023.htm (accessed 2010 Dec 20).
21. 111th Congress, Second Session. Compilation of Patient Protection and Affordable Care Act: as amended through November 1, 2010 including Patient Protection and Affordable Care Act health-related portions of the Health Care and Education Reconciliation Act of 2010. http://frwebgate.access.gpo.gov/cgi- bin/ getdoc.cgi?dbname=111-cong-house- committee-prints&docid=f:61643.pdf (accessed 2011 Feb 8).
22. Health Resources and Services Administration. Affordable Care Act entities. www.hrsa.gov/opa/acaentities.htm (accessed 2010 Dec 20).
23. Hall MA. Health care reform - what went wrong on the way to the courthouse. N Engl J Med. 2011; 364:295-7.
24. Klein E. Health-care overhaul's individual mandate makes all the difference. www.washingtonpost.com/wp-dyn/ content/article/2010/12/17/ AR2010121702366.html (accessed 2010 Dec 18).
25. Orszag PR, Emanuel EJ. Health care reform and cost control. N Engl J Med. 2010; 363:601-3.
26. Kocher R, Sahni N. Physicians versus hospitals as leaders of accountable care organizations. N Engl J Med. 2010; 27: 2579-82.
27. Food and Drug Administration. Approval pathway for biosimilar and interchangeable biological products public meeting. www.fda.gov/Drugs/News Events/ucm221688.htm (accessed 2010 Dec 22).
28. Schellekens H, Moors E. Clinical comparability and European biosimilar regulations. Nat Biotechnol. 2010; 28:28-31.
29. Traynor K. Drug shortages mount in 2010. Am J Health-Syst Pharm. 2010; 67:1492,1494. News.
30. American Society of Health-System Pharmacists. Drug shortages summit report. www.ashp.org/drugshortages/ summitreport (accessed 2011 Jan 24).
31. Stubbings J, Joshi RA, Hoffman JM. Risk evaluation and mitigation strategies: challenges and opportunities for health-system pharmacists. Am J Health-Syst Pharm. 2010; 67:1547-54.
32. Express Scripts. 2009 drug trend report. www.express-scripts.com/ research/ studies/drugtrendreport (accessed 2010 Nov 20).
33. Sisko AM, Truffer CJ, Keehan SP et al. National health spending projections: the estimated impact of reform through 2019. Health Aff. 2010; 29:1933-41.
34. Centers for Medicare and Medicaid Services. National health expenditure projections, 2009-2019. www.cms.gov/ NationalHealthExpendData/Downloads/ proj2009.pdf (accessed 2010 Nov 20).
35. Centers for Medicare and Medicaid Services. National health expenditure tables. www.cms.gov/NationalHealthExpend Data/downloads/tables.pdf (accessed 2011 Jan 27).
36. American Society of Health-System Pharmacists. ASHP guidelines on medication cost management strategies for hospitals and health systems. Am J Health-Syst Pharm. 2008; 65:1368-84.